[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353785-105":59,"doc-detail-353785-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mitochondrial-targets-in-idh1-mutated-cholangiocarcinoma","Mitochondrial targets in IDH1-mutated cholangiocarcinoma","","Cholangiocarcinoma (CCA), a biliary tract cancer subset, remains difficult to treat and carries poor long-term survival despite recent targeted-therapy advances. Emerging findings indicate that IDH1-mutated CCA has distinct mitochondrial vulnerabilities. This report reviews mitochondrial metabolism as a therapeutic target, emphasizing preclinical support for inhibiting the tricarboxylic acid (TCA) cycle and glutamine metabolism and considering combination approaches for future clinical translation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mitochondrial-targets-in-idh1-mutated-cholangiocarcinoma/353785/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mitochondrial-targets-in-idh1-mutated-cholangiocarcinoma/353785.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is mitochondrial metabolism considered a target in IDH1-mutated cholangiocarcinoma?","Question",{"text":113,"@type":114},"Recent data suggest IDH1-mutated CCA shows unique mitochondrial vulnerabilities, making mitochondrial metabolism an actionable therapeutic area. The report discusses preclinical evidence supporting metabolic inhibition strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is ivosidenib and what benefit has it shown in advanced CCA?",{"text":118,"@type":114},"Ivosidenib is a reversible inhibitor of mutant IDH1 and is FDA-approved as subsequent-line therapy. In the ClarIDHy phase 3 trial, it improved median progression-free survival versus placebo.",{"name":120,"@type":111,"acceptedAnswer":121},"Why might inhibiting mutant IDH1 alone be insufficient, and what resistance mechanisms exist?",{"text":122,"@type":114},"The report notes that plasma 2-HG suppression does not correlate with overall response and that additional tumor benefit may require more than 2-HG reduction. Resistance mechanisms include acquired mutations, isoform switching between IDH1 and IDH2, MAPK pathway activation, and secondary IDH mutations affecting inhibitor binding.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353785,1790763606,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Received: 17 July 2025 | Accepted: 12 January 2026  \nDOI: 10. 1097/HC9 .0000000000000909  \nRESEARCH LETTER  \nMitochondrial targets in IDH1-mutated cholangiocarcinoma  \nCamila Carvalho 1  | Fulei Wuchu2,3 | Nicole Peterson1 | Deepak Nagrath2,3,4 | Arathi Mohan1,5  | Vaibhav Sahai1,5   \n1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA  \n2Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA 3Laboratory for Systems Biology of Human Diseases, University of Michigan, Ann Arbor, Michigan, USA 4Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, USA  \n5Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA  \nCorrespondence  \nVaibhav Sahai, MBBS, MS Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.  \nEmail: [vsahai@umich.edu](vsahai@umich.edu)  \nAbstract  \nCholangiocarcinoma (CCA), a subset of biliary tract cancers, remains a therapeutically challenging malignancy with poor long-term survival despite recent advances in targeted therapies. Recent data suggest that IDH1-mutated CCA exhibits unique mitochondrial vulnerabilities. In this report, we discuss the emerging role of mitochondrial metabolism as a target in IDH1-mutated CCA, including preclinical evidence supporting the inhibition of the tricarboxylic acid (TCA) cycle, glutamine metabolism, and potential combination approaches. We aim to highlight the growing need to integrate mitochondrial-targeted strategies into future clinical investigations.  \nKeywords: cholangiocarcinoma, ivosidenib, mutant isocitrate dehydrogenase, targeted therapy  \nINTRODUCTION  \nBiliary tract cancer (BTC) encompasses a rare and aggressive group of tumors, including cholangiocarcinoma (CCA) and gallbladder cancer, with poor survival despite advances in targeted and immune checkpoint therapies. BTCs exhibit altered cellular metabolism,  \nincluding enhanced mitochondrial metabolism and oxidative phosphorylation for tumor growth and chemotherapy resistance.[1–3] Intrahepatic CCA harbors mutations in the isocitrate dehydrogenase (IDH) genes, with IDH1 and IDH2 mutations detected in 10%–15% and 1%–2% tumors, respectively. IDH, a key enzyme in the tricarboxylic acid (TCA) cycle, catalyzes the reversible  \nAbbreviations: BTC, biliary tract cancer; CCA, cholangiocarcinoma; GLS1, glutaminase; IDH, isocitrate dehydrogenase; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; NAMPT, nicotinamide phosphoribosyl transferase; PARP, poly ADP ribose polymerase; TCA, tricarboxylic acid; α-KG, α-ketoglutarate.  \nCamila Carvalho, Fulei Wuchu, Arathi Mohan, and Vaibhav Sahai have contributed equally to this work.  \nCamila Carvalho and Fulei Wuchu-co-first authorsArathi Mohan and Vaibhav Sahai-co-last authors  \nSupplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www. hepcommjournal.com.  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nCopyright © 2026 The Author(s) . Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.  \nnicotinamide-adenine dinucleotide phosphate (NADP +)-dependent oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) and NADPH. These IDH1 and IDH2 hotspot driver mutations result in neomorphic enzymatic activity, leading to the conversion of α-KG to R-2-hydroxyglutarate (2-HG)[10] . R-2-HG, an oncometabolite, causes epigenetic alterations resulting indistinct histone and DNA methylation patt","cbCaifwezqJjMBOj","https://ap.wps.com/l/cbCaifwezqJjMBOj","pdf",2947600,"English","# Introduction\n# Metabolic vulnerabilities in IDH-mutated CCA\n## IDH1 protein\n## Ivosidenib and clinical outcomes\n## Resistance mechanisms and combination rationale","[{\"question\":\"Why is mitochondrial metabolism considered a target in IDH1-mutated cholangiocarcinoma?\",\"answer\":\"Recent data suggest IDH1-mutated CCA shows unique mitochondrial vulnerabilities, making mitochondrial metabolism an actionable therapeutic area. The report discusses preclinical evidence supporting metabolic inhibition strategies.\"},{\"question\":\"What is ivosidenib and what benefit has it shown in advanced CCA?\",\"answer\":\"Ivosidenib is a reversible inhibitor of mutant IDH1 and is FDA-approved as subsequent-line therapy. In the ClarIDHy phase 3 trial, it improved median progression-free survival versus placebo.\"},{\"question\":\"Why might inhibiting mutant IDH1 alone be insufficient, and what resistance mechanisms exist?\",\"answer\":\"The report notes that plasma 2-HG suppression does not correlate with overall response and that additional tumor benefit may require more than 2-HG reduction. Resistance mechanisms include acquired mutations, isoform switching between IDH1 and IDH2, MAPK pathway activation, and secondary IDH mutations affecting inhibitor binding.\"}]","Mitochondrial targets in IDH1-mutated cholangiocarcinoma | PDF",1790107231,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff45cf8b9b89def50692ee1d31b01865.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/876dfc1d34bf610c8560094978c30ea7.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb63e67a973847645478756e914ae863.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/293205f2caa323a388f7e7bb100a9982.webp",980,1292]